Recursion Pharmaceuticals, Inc. RXRX FX Effect on Cash
FX Effect on Cash at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s fx effect on cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s FX effect on cash?
- Recursion Pharmaceuticals, Inc. (RXRX) reported FX effect on cash of -$3.83M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s FX effect on cash changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s FX effect on cash decreased by 179.3% year-over-year, from $4.83M to -$3.83M.
- What does FX effect on cash mean?
- The impact of exchange rate changes on the value of cash and equivalents held in foreign currencies.